MapLight Therapeutics, Inc. 8-K

What Happened
MapLight Therapeutics, Inc. (MPLT) filed a Form 8-K on July 27, 2026 disclosing that it will hold a conference call that day to discuss topline results from ZEPHYR, a Phase 2 trial of ML-007C-MA in inpatient adult participants with schizophrenia experiencing an acute exacerbation of psychosis. The company furnished the presentation for the call and issued a press release announcing the ZEPHYR Trial Results.

Key Details

• Date of disclosure and events: July 27, 2026 (8-K filed the same day).
• Trial and drug: ZEPHYR Phase 2 trial of ML-007C-MA in inpatient adults with schizophrenia during an acute psychosis exacerbation.
• Materials filed: Company presentation accompanying the call (Exhibit 99.1) and press release announcing results (Exhibit 99.2).
• Form items cited: Item 7.01 (Regulation FD disclosure) and Item 8.01 (Other events/press release).

Why It Matters
Topline Phase 2 results are a key clinical milestone that can affect development decisions, partnering interest and investor sentiment for a clinical-stage biotech. By filing an 8-K and issuing a press release under Regulation FD, MapLight made the results public and provided materials investors can review immediately (presentation and press release) to assess the implications for the company’s pipeline and strategy.